What Tarsus Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 14 | 59 |
| Total trades | 17 | 82 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 704 | 239,960 |
| Disposed | 62,595 | 324,392 |
| Net activity | −61,891 | −84,432 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yarno Wendy L | Director | Sep 15 | Exercise / conversion · M | +302 | — | — | 16,956 |
| Link William J Phd | Director | Sep 15 | Disclosed 10b5-1 sale · S | −66 | $80.01 | −$5.28K | 94,487 |
| Link William J Phd | Director | Sep 15 | Disclosed 10b5-1 sale · S | −759 | $79.00 | −$60K | 94,553 |
| Link William J Phd | Director | Sep 15 | Disclosed 10b5-1 sale · S | −11,675 | $78.33 | −$915K | 95,312 |
| Link William J Phd | Director | Sep 15 | Exercise / conversion · M | +201 | — | — | 106,987 |
| Pyott David E I | Director | Sep 15 | Exercise / conversion · M | +201 | — | — | 9,575 |
| Neervannan Seshadri | Chief Operating Officer | Sep 04 | Disclosed 10b5-1 sale · S | −4,564 | $85.00 | −$388K | 78,532 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 04 | Disclosed 10b5-1 sale · S | −1,590 | $90.00 | −$143K | 1,590 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 04 | Disclosed 10b5-1 sale · S | −1,590 | $85.00 | −$135K | 3,180 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 04 | Disclosed 10b5-1 sale · S | −5,386 | $90.00 | −$485K | 2,547 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 04 | Disclosed 10b5-1 sale · S | −5,387 | $85.00 | −$458K | 7,933 |
| Azamian Bobak R. | President/CEO and Board Chair | Sep 04 | Disclosed 10b5-1 sale · S | −2,900 | $91.27 | −$265K | 827,991 |
| Azamian Bobak R. | President/CEO and Board Chair | Sep 04 | Disclosed 10b5-1 sale · S | −7,100 | $90.27 | −$641K | 830,891 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 02 | Disclosed 10b5-1 sale · S | −1,590 | $80.00 | −$127K | 4,770 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 02 | Disclosed 10b5-1 sale · S | −5,387 | $80.00 | −$431K | 13,320 |
| Azamian Bobak R. | President/CEO and Board Chair | Sep 02 | Disclosed 10b5-1 sale · S | −10,000 | $80.06 | −$801K | 837,991 |
| Lin Elizabeth Yeu | Chief Medical Officer | Sep 01 | Disclosed 10b5-1 sale · S | −4,601 | $73.86 | −$340K | 18,707 |
| Azamian Bobak R. | President/CEO and Board Chair | Jun 17 | Disclosed 10b5-1 sale · S | −5,418 | $61.81 | −$335K | 847,991 |
| Azamian Bobak R. | President/CEO and Board Chair | Jun 17 | Disclosed 10b5-1 sale · S | −4,582 | $61.24 | −$281K | 853,409 |
| Farrow Jeffrey S | See Remarks | Jun 16 | Open-market sale · S | −14,396 | $60.95 | −$877K | 56,801 |
Loading...